EUVIMEDEUVIMED entdecken
Crossref

Impact of Concurrent Genomic Alterations on Clinical Outcomes in Patients With ALK-Rearranged NSCLC

Luis Lara-Mejía, Andres F Cardona, Luis Mas, Claudio Martin, Suraj Samtani, Luis Corrales, Graciela Cruz-Rico, Jordi Remon, Marco Galvez-Nino, Rossana Ruiz, Eduardo Rios-Garcia, Fernanda Tejada und 3 weitere

Journal of Thoracic Oncology · 2024-01 · 19 (1) · 119-129

DOI: 10.1016/j.jtho.2023.08.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thoracic Oncology, 2024-01. Verfasst von Luis Lara-Mejía und 14 weiteren Autor:innen. Beteiligte Einrichtung: Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), ad0h0, Mexico City, Mexico. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: ALK tyrosine kinase inhibitors have exhibited promising activity against advanced ALK-rearranged NSCLC. However, co-occurring genetic alterations, such as CDKN2A/B or TP53, may negatively affect the efficacy of targeted therapies. METHODS: From December 2017 to December 2022, this study cohort analyzed next-generation sequencing data of 116 patients with metastatic ALK-rearranged NSCLC from five Latin American cancer centers. Clinicopathologic and molecular features were associated with clinical outcomes and risk of brain metastasis (BrM) in patients with and without concurrent somatic alterations. RESULTS: All patients (N = 116) received a second-generation ALK tyrosine kinase inhibitor, and alectinib was selected in 87.2% of cases. Coalterations occurred in 62% of the cases; the most frequent were TP53 mutations (27%) and CDKN2A/B loss (18%). The loss of CDKN2A/B was associated with an increased risk of BrM, with a cumulative incidence of 33.3% versus 7.4% in the non-coaltered subgroup. Compared with patients without coalterations, patients with concurrent CDKN2A/B loss (n = 21) had a shorter median progression-free survival (10.2 versus 34.2 mo, p < 0.001) and overall survival (26.2 versus 80.7 mo, p < 0.001). In the multivariate analysis, co-occurring CDKN2A/B loss was associated with poorer progression-free survival and OS despite the presence of other somatic coalterations, TP53 mutations, BrM, and Eastern Cooperative Oncology Group Performance Status. CONCLUSIONS: This study confirmed the worse prognostic value, which depicted co-occurring alterations in patients with ALK rearrangement. CDKN2A/B loss was substantially associated with worse outcomes and a higher risk of brain metastases. The evidence presented in our study may help select patients with ALK-positive tumors suitable for treatment escalation and closer brain follow-up.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCarcinoma, Non-Small-Cell LungHumansAnaplastic Lymphoma KinaseProtein Kinase InhibitorsGenomics

Stichwörter der Autor:innen

ALK-rearrangedCDKN2A/BConcurrent genomic alterationsNext-generation sequencingNon–small cell lung cancer

Substanzen

Anaplastic Lymphoma KinaseProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), ad0h0, Mexico City, Mexico.
  • Direction of Research, Science, and Education, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogotá, Colombia.
  • Medical Oncology Unit, Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima, Peru; Clinical Trials Unit, AUNA Ideas, Lima, Peru.
  • Thoracic Oncology Unit, Alexander Fleming Institute, Buenos Aires, Argentina.
  • Medical Oncology Department, Clínica Las Condes Santiago, Las Condes, Chile.
  • Thoracic Oncology Unit, Centro de Investigación y Manejo del Cancer (CIMCA), San Jose, Costa Rica.

Zitieren

APA

Lara-Mejía, L., Cardona, A. F., Mas, L., Martin, C., Samtani, S., Corrales, L., Cruz-Rico, G., Remon, J., Galvez-Nino, M., Ruiz, R., Rios-Garcia, E., Tejada, F., Lozano-Vazquez, N., Rosell, R., & Arrieta, O. (2024). Impact of Concurrent Genomic Alterations on Clinical Outcomes in Patients With ALK-Rearranged NSCLC. Journal of Thoracic Oncology, 19(1), 119-129. https://doi.org/10.1016/j.jtho.2023.08.007

Vancouver

Lara-Mejía L, Cardona AF, Mas L, Martin C, Samtani S, Corrales L, et al. Impact of Concurrent Genomic Alterations on Clinical Outcomes in Patients With ALK-Rearranged NSCLC. Journal of Thoracic Oncology. 2024;19(1):119-129. doi:10.1016/j.jtho.2023.08.007

BibTeX
@article{LaraMeja2024,
  author = {Lara-Mejía, Luis and Cardona, Andres F and Mas, Luis and Martin, Claudio and Samtani, Suraj and Corrales, Luis and Cruz-Rico, Graciela and Remon, Jordi and Galvez-Nino, Marco and Ruiz, Rossana and Rios-Garcia, Eduardo and Tejada, Fernanda and Lozano-Vazquez, Natalia and Rosell, Rafael and Arrieta, Oscar},
  title = {Impact of Concurrent Genomic Alterations on Clinical Outcomes in Patients With ALK-Rearranged NSCLC},
  journal = {Journal of Thoracic Oncology},
  year = {2024},
  volume = {19},
  number = {1},
  pages = {119--129},
  doi = {10.1016/j.jtho.2023.08.007}
}
Kostenlos starten →